hepatitis B
BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-na  ve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-a and nucleoside analogue therapies.